HFS
REGN icon

Hantz Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Hantz Financial Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Buy
447
+4
+0.9% +$2.72K ﹤0.01% 971
2026
Q1 		$342K Buy
443
+172
+63% +$132K 0.01% 796
2025
Q4 		$209K Buy
271
+93
+52% +$63.2K ﹤0.01% 852
2025
Q3 		$100K Buy
178
+70
+65% +$39.6K ﹤0.01% 971
2025
Q2 		$57K Buy
108
+44
+69% +$24.6K ﹤0.01% 930
2025
Q1 		$41K Sell
64
-9
-12% -$6.19K ﹤0.01% 733
2024
Q4 		$52K Hold
73
– – ﹤0.01% 660
2024
Q3 		$77K Buy
73
+34
+87% +$37.8K ﹤0.01% 629
2024
Q2 		$41K Buy
39
+5
+15% +$4.85K ﹤0.01% 678
2024
Q1 		$33K Hold
34
– – ﹤0.01% 697
2023
Q4 		$30K Hold
34
– – ﹤0.01% 693
2023
Q3 		$28K Sell
34
-23
-40% -$18.1K ﹤0.01% 690
2023
Q2 		$41K Sell
57
-33
-37% -$25.4K ﹤0.01% 641
2023
Q1 		$74K Hold
90
– – ﹤0.01% 590
2022
Q4 		$65K Sell
90
-31
-26% -$22.9K ﹤0.01% 595
2022
Q3 		$83K Sell
121
-12
-9% -$7.55K ﹤0.01% 564
2022
Q2 		$79K Sell
133
-30
-18% -$19.5K ﹤0.01% 565
2022
Q1 		$114K Sell
163
-188
-54% -$119K ﹤0.01% 563
2021
Q4 		$222K Buy
351
+139
+66% +$85.5K 0.01% 501
2021
Q3 		$128K Sell
212
-3
-1% -$1.86K ﹤0.01% 523
2021
Q2 		$120K Sell
215
-84
-28% -$42.6K ﹤0.01% 503
2021
Q1 		$141K Sell
299
-24,961
-99% -$12.2M 0.01% 464
2020
Q4 		$12.2M Buy
25,260
+777
+3% +$419K 0.55% 44
2020
Q3 		$13.7M Buy
24,483
+1,136
+5% +$689K 0.7% 31
2020
Q2 		$14.6M Buy
23,347
+1,125
+5% +$639K 0.81% 26
2020
Q1 		$10.9M Buy
+22,222
New +$9.17M 0.75% 28

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hantz Financial Services's REGN Position: Q2 2026 in Review

Hantz Financial Services increased its Regeneron Pharmaceuticals (REGN) stake by 0.9% in Q2 2026, buying an estimated $2.72K and bringing the position to 447 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #971.

Hantz Financial Services first reported a position in REGN in Q1 2020 and has held it in 26 quarters since. The position peaked at $14.6M in Q2 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Hantz Financial Services held 447 shares of Regeneron Pharmaceuticals worth $279K as of Q2 2026.
  • Hantz Financial Services bought 4 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.72K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #971 holding.
  • Hantz Financial Services first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Hantz Financial Services's Regeneron Pharmaceuticals position peaked at $14.6M in Q2 2020.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.